about
Magnetic resonance imaging changes of sacroiliac joints in patients with recent-onset inflammatory back pain: inter-reader reliability and prevalence of abnormalitiesEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateClinical Tools to Assess and Monitor SpondyloarthritisDefining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group.Analysis of integrated radiographic data from two long-term, open-label extension studies of adalimumab for the treatment of rheumatoid arthritis.Radiographic progression depicted by probability plots: presenting data with optimal use of individual values.Metric Properties of the SPARCC Score of the Sacroiliac Joints - Data from Baseline, 3-month, and 12-month Followup in the SPACE Cohort.Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study.Does body mass index (BMI) influence the Ankylosing Spondylitis Disease Activity Score in axial spondyloarthritis?: Data from the SPACE cohortShort-term changes on MRI predict long-term changes on radiography in rheumatoid arthritis: an analysis by an OMERACT Task Force of pooled data from four randomised controlled trials.Searching for potential biomarkers that can be used as biomarkers for diagnosing ankylosing spondylitis.EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology.The performance of different classification criteria sets for spondyloarthritis in the worldwide ASAS-COMOSPA study.Is the current ASAS expert definition of a positive family history useful in identifying axial spondyloarthritis? Results from the SPACE and DESIR cohorts14-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damageEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsCurrent evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis.Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort.Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology.Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis.DAS steered therapy in clinical practice; cross-sectional results from the METEOR databaseHow do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis?Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis.Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.Sponyloarthritis features forecasting the presence of HLA-B27 or sacroiliitis on magnetic resonance imaging in patients with suspected axial spondyloarthritis: results from a cross-sectional study in the ESPeranza Cohort.Imaging in spondylitis.Associations between the PTPN22 1858C->T polymorphism and radiographic joint destruction in patients with rheumatoid arthritis: results from a 10-year longitudinal studyHow should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured?Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysisCardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts.Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?Association of early radiographic damage with impaired physical function in rheumatoid arthritis: a ten-year, longitudinal observational study in 238 patients.Imaging in ankylosing spondylitis.Social Role Participation Questionnaire for patients with ankylosing spondylitis: translation into Dutch, reliability and construct validity.
P50
Q21092909-B3E97BC6-ADE9-4319-83B1-E9F439C17299Q26859134-FC2AB9F4-011D-4574-BFCA-BE9A5027FE84Q26866120-75128989-AB72-4727-973F-B39D7549DAE8Q30251968-ED8755E5-6B97-4173-853C-8ECF1E923536Q30839439-2CFC7C79-C976-43A8-B03B-02C730CED835Q30912433-D9FB4203-D129-4936-92DE-E822F7A0482DQ30942425-873D1DF6-A62F-435F-ACA5-29772F6A7F5AQ30980061-713C0CE7-8C5D-42CF-871E-6E67C04E713CQ31113992-0BADA9EF-1CC7-451E-94DC-B169FB651F16Q31148860-7D97B125-44E5-4B1F-898A-3A0A3E2AEA4EQ33579369-CAF6B223-889A-4D36-8080-B79F990FB7CFQ33595690-F8123C49-BA16-4B62-BD64-03DD7E02B695Q33696947-8771DFFC-5FB0-4BBE-8989-8C0BBF051CAAQ33750589-5D732A3D-DFBD-4F77-8FC8-626FF17DD53BQ33766367-BF7B818E-A150-4D36-9B9F-81430FBFABB7Q34110066-C4F479DC-E6F1-4C13-9662-13C3D89DE0FBQ34113970-B09CBE2E-9116-4282-8FF6-DA3AA24C2F45Q34237578-8DC5853F-5E8F-4BE7-86CB-6CAF11AB920EQ34270783-DE4098AB-E6D1-4D2E-A1DB-4181FC5F3EE9Q34607794-73BA6D59-A1FF-4A18-9920-7E6B6AD67FA8Q34609376-45861A61-D38B-49DF-AFFA-6EF6BA28F1CDQ35047250-975A371F-1AFC-4916-BBF3-135FDD394037Q35084199-72B00FF4-C248-4405-B485-A9044A265ED9Q35165774-296AF93D-77CE-4984-97C3-71884BAB8D7BQ35605474-B42FCC9A-BC30-4DC6-8F9C-E5376F6677D8Q35632933-670A3F94-FC57-46F7-9C5B-4DE40188E17BQ35895890-84DBE5F7-6086-437B-94D9-9F3A0D0CD3AFQ35953430-400C61BB-E375-4CF8-9A08-6111ABBB5C3EQ35953503-48FD78B8-BB77-4D27-84B2-D2B4B5E2A2CBQ36045392-235AF8E6-0FDD-48FB-AED2-F1B2325C8286Q36085982-4D0FE3DA-B818-485A-B915-4E4C8ADF2CFDQ36163438-F1551FCA-1644-434C-A746-8330C5F86866Q36171863-A83A3264-907B-4649-841F-A428CBD24404Q36178464-DE4F8286-146D-4EA4-8C09-EA9ACB2F9DC5Q36215822-9A0D64E3-82A1-40C0-BB72-036C83148893Q36215867-FA0654D0-0954-4C04-8609-6B454F21B18DQ36302246-B39C8EDE-115B-49FD-9622-6A17257F91F8Q36356750-40910811-B5A0-4764-BADF-B1A1815AF95AQ36507966-8F8C3FB7-A809-418E-9CCC-92E075715CB5Q36559847-22D4E38A-428E-4263-9BFD-0223D79AEE3B
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
researcher
@en-gb
ricercatore
@it
հետազոտող
@hy
name
Robert Landewé
@ast
Robert Landewé
@br
Robert Landewé
@ca
Robert Landewé
@cs
Robert Landewé
@cy
Robert Landewé
@da
Robert Landewé
@de
Robert Landewé
@de-at
Robert Landewé
@de-ch
Robert Landewé
@en
type
label
Robert Landewé
@ast
Robert Landewé
@br
Robert Landewé
@ca
Robert Landewé
@cs
Robert Landewé
@cy
Robert Landewé
@da
Robert Landewé
@de
Robert Landewé
@de-at
Robert Landewé
@de-ch
Robert Landewé
@en
altLabel
R. Landewé
@nl
prefLabel
Robert Landewé
@ast
Robert Landewé
@br
Robert Landewé
@ca
Robert Landewé
@cs
Robert Landewé
@cy
Robert Landewé
@da
Robert Landewé
@de
Robert Landewé
@de-at
Robert Landewé
@de-ch
Robert Landewé
@en
P1006
P214
P1006
P106
P1153
7006658098
P21
P213
0000 0003 5772 4045
P214
P31
P496
0000-0002-0577-6620
P569
1964-01-01T00:00:00Z
P735
P7449
PRS1307959
P7859
viaf-200237207